Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 172-183 , February 2006

Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol

  • Iván Alvarez

      Affiliations

    • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Anna Sureda

      Affiliations

    • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • Corresponding Author InformationCorrespondence and reprint requests: Anna Sureda, MD, Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Antoni Maria I Claret, 167, 08025 Barcelona, Spain
    • ,
  • Maria D. Caballero

      Affiliations

    • Hospital Clínico, Salamanca, Spain
    • ,
  • Alvaro Urbano-Ispizua

      Affiliations

    • Hospital Clínic i Provincial, Barcelona, Spain
    • ,
  • Josep M. Ribera

      Affiliations

    • Hospital Germans Trias i Pujol, Barcelona, Spain
    • ,
  • Miguel Canales

      Affiliations

    • Hospital La Paz, Madrid, Spain
    • ,
  • Javier García-Conde

      Affiliations

    • Hospital Clínico y Provincial, Valencia, Spain
    • ,
  • Guillermo Sanz

      Affiliations

    • Hospital La Fe, Valencia, Spain
    • ,
  • Reyes Arranz

      Affiliations

    • Hospital La Princesa, Madrid, Spain
    • ,
  • Maria T. Bernal

      Affiliations

    • Hospital General de Oviedo, Oviedo, Spain
    • ,
  • Javier de la Serna

      Affiliations

    • Hospital Doce de Octubre, Madrid, Spain
    • ,
  • José L. Díez

      Affiliations

    • Hospital Gregorio Marañón, Madrid, Spain
    • ,
  • José M. Moraleda

      Affiliations

    • Hospital Morales Messeguer, Murcia, Spain
    • ,
  • Daniel Rubió-Félix

      Affiliations

    • Hospital Miguel Servet, Zaragoza, Spain
    • ,
  • Blanca Xicoy

      Affiliations

    • Hospital Germans Trias i Pujol, Barcelona, Spain
    • ,
  • Carmen Martínez

      Affiliations

    • Hospital Clínic i Provincial, Barcelona, Spain
    • ,
  • Marivi V. Mateos

      Affiliations

    • Hospital Clínico, Salamanca, Spain
    • ,
  • Jorge Sierra

      Affiliations

    • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Received 11 May 2005 ,Accepted 20 September 2005.

References 

  1. Diehl V , Franklin J , Hasenclever D , et al.   BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma (interim report from a trial of the Germany Hodgkin’s Lymphoma Study Group) . J Clin Oncol . 1998;16:3810–3821
  2. Horning SJ , Williams J , Bartlett NL , et al.   Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease (Eastern Cooperative Oncology Group Pilot Study E1492) . J Clin Oncol . 2000;18:972–980
  3. Longo DL , Duffey PL , Young RC , et al.   Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy (the low probability for cure) . J Clin Oncol . 1992;10:210–218
  4. Bonfante V , Santoro A , Viviani S , et al.   Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD . J Clin Oncol . 1997;15:528–534
  5. Linch DC , Winfield D , Goldstone AH , et al.   Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease (results of a BNLI randomised trial) . Lancet . 1993;341:1051–1054
  6. Schmitz N , Pfistner B , Sextro M , et al.   Aggressive conventional chemotherapy compared with high-dose chemotherapy requiring autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease (a randomised trial) . Lancet . 2002;359:2065–2071
  7. Jones RJ , Ambinder RF , Piantadosi S , et al.   Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation . Blood . 1991;77:649–653
  8. Anderson JE , Litzow MR , Appelbaum FR , et al.   Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease (the 21-year Seattle experience) . J Clin Oncol . 1993;11:2342–2350
  9. Akpek G , Ambinder RF , Piantadosi S , et al.   Long-term results of blood and marrow transplantation for Hodgkin’s Lymphoma . J Clin Oncol . 2001;19:4314–4321
  10. Porter DL , Stadtmauer EA , Lazarus HM . GVHD: graft-versus-host-disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning . Bone Marrow Transplant . 2003;31:739–746
  11. Gajewski JL , Phillips GL , Sobocinski KA , et al.   Bone marrow transplantation from HLA-identical siblings in advanced Hodgkin’s disease . J Clin Oncol . 1996;14:572–578
  12. Milpied N , Fielding AK , Pierce RM , et al.   Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease . J Clin Oncol . 1996;14:1291–1296
  13. Storb R , Yu G , John L , et al.   Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation . Blood . 1997;89:3048–3054
  14. Giralt S , Estey E , Albitar M , et al.   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (harnessing graft-versus-leukemia without myeloablative therapy) . Blood . 1997;89:4531–4536
  15. Slavin S , Nagler A , Naparstek E , et al.   Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with cytoreduction for the treatment of malignant and non-malignant hematologic diseases . Blood . 1998;91:756–763
  16. Porter DL , Roth MS , McGarigle C , Ferrara JLM , Antin JH . Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia . N Engl J Med . 1994;330:100–106
  17. Kolb HJ , Schattenberg A , Goldman J , et al.  European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia   Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients . Blood . 1995;86:2041–2050
  18. Collins RH , Shpilberg O , Drobyski WR , et al.   Donor leukocyte infusions in 140 patients relapsed with malignancy after allogeneic bone marrow transplantation . J Clin Oncol . 1997;15:433–444
  19. Anderlini P , Saliba R , Acholonu S , et al.   Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease (low transplant-related mortality and impact of intensity of conditioning regimen) . Bone Marrow Transplant . 2005;35:943–951
  20. Carella AM , Cavaliere M , Lerma E , et al.   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hemopoietic stem cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma . J Clin Oncol . 2000;18:3918–3924
  21. Robinson S , Taghipour G , Sureda A . Reduced intensity allogeneic stem cell transplantation for Hodgkin’s disease. Outcome depends primarily on disease status at the time of transplantation . Blood . 2004;104:639a
  22. Burroughs LM , Maris MB , Sandmaier BM , et al.   HLA-matched related or unrelated donor nonmyeloablative conditioning and hematopoietic cell transplant for patients with advanced Hodgkin disease . Biol Blood Marrow Transplant . 2004;10(suppl 1):73
  23. Peggs KS , Hunter A , Parker A , et al.   Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation . Lancet . 2005;365:1934–1941
  24. Przepiorka D , Weisdorf D , Martín P , et al.   Consensus conference on acute GVHD grading . Bone Marrow Transplant . 1995;15:825–830
  25. Sullivan KM , Shulman HM , Storb R , et al.   Chronic-graft-versus-host disease in 52 patients (adverse natural course and successful treatment with combined immunosuppression) . Blood . 1981;57:267–276
  26. Pérez-Simón JA , Caballero MD , Díez-Campelo M , et al.   Chimerism and minimal residual disease monitoring after reduced intensity conditioning allogeneic transplantation . Leukemia . 2002;16:1423–1431
  27. Valcárcel D , Martino R , Caballero MD , et al.   Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning . Bone Marrow Transplant . 2003;31:387–392
  28. Carbone PP , Kaplan HD , Musshogg K , et al.   Report of the Committee of Hodgkin’s Disease Staging . Cancer Res . 1971;31:1860–1861
  29. Cheson BD , Horning SJ , Coiffier B , et al.   Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas . J Clin Oncol . 1999;17:1244–1253
  30. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457–481
  31. Mantel N , Haenzel W . Statistical aspects of the analysis of data from retrospective studies of disease . J Natl Cancer Inst . 1958;22:719–723
  32. Kottaridis PD , Milligan D , Chopra R , et al.   In vivo alemtuzumab prevents graft-versus-host-disease following non-myeloablative stem cell transplantation . Blood . 2000;96:2419–2425
  33. Martino R , Caballero D , Canals C , et al.   Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning (results of a prospective multicenter study) . Br J Haematol . 2001;115:653–659
  34. Gómez-Núñez M , Martino R , Caballero MD , et al.   Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning (results from the Spanish multicenter prospective trial) . Bone Marrow Transplant . 2004;33:477–482
  35. Branson K , Chopra R , Kottaridis PD , et al.   Role of non-myeloablative stem cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies . J Clin Oncol . 2002;20:4022–4031
  36. Sureda A , Robinson S , Ruiz de Elvira C , et al.   Non myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin’s disease (results of the European Group for Blood and Marrow Transplantation) . Blood . 2003;100(suppl 1):198a
  37. Pérez-Simón JA , Kottaridis PD , Martino R , et al.   Nonmyeloablative transplantation with or without alemtuzumab (comparison between 2 prospective studies in patients with lymphoproliferative disorders) . Blood . 2002;100:3121–3127
  38. Peggs K , Sureda A , Hunter A , et al.   Impact of in vivo T-cell depletion on outcome following reduced intensity transplantation for Hodgkin’s lymphoma (comparison between two prospective studies) . Blood . 2004;104:230a

PII: S1083-8791(05)00673-7

doi: 10.1016/j.bbmt.2005.09.009

Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 172-183 , February 2006

Article Tools

* Image Usage & Resolution